The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET TM ) showed that the angiotensin II receptor blocker (ARB) telmisartan was as protective as the reference-standard ramipril in a broad cross-section of patients at increased cardiovascular risk, but was better tolerated. Telmisartan has a unique profile among ARBs, with a high affinity for the angiotensin II type 1 receptor, a long duration of receptor binding, a high lipophilicity and a long plasma half life. This leads to sustained and powerful blood pressure lowering when compared with the first marketed ARBs, such as losartan and valsartan. Some pharmacological properties of telmisartan clearly distinguish it from other members of the ARB class and may contribute to the clinical effects seen with telmisartan. A class effect for ARBs cannot be assumed. To date, telmisartan is the only ARB that has been shown to reduce cardiovascular risk in at-risk cardiovascular patients.
Introduction
The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET TM ), which compared the cardiovascular protective effects of telmisartan (80 mg/day) and ramipril (10 mg/day) in patients at increased cardiovascular risk (i.e. with vascular disease or diabetes with concomitant end-organ damage), is a major recent development in preventive medicine. 1 ONTARGET™ was the first study to show that an angiotensin II receptor blocker (ARB) was as effective as an angiotensin-converting enzyme (ACE) inhibitor in at-risk patients. 1 Telmisartan prevented the primary outcome (a composite of cardiovascular death, myocardial infarction [MI], stroke or hospitalization for heart failure) in a broad cross-section of ACE inhibitor-tolerant patients to the same extent as ramipril, while being better tolerated and associated with higher treatment persistence. 1 Although a few other ARB cardiovascular outcome trials have been conducted, telmisartan is the only ARB to date to have been studied in a broad cross-section of atrisk patients. For example, the Valsartan
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Antihypertensive Long-term Use Evaluation (VALUE) trial 2 and the Losartan Intervention For Endpoint reduction in hypertension (LIFE) 3 trial recruited patients with higher blood pressure and lower additional risk, while other ARB outcome trials recruited patients at very high risk (for example post-MI or with heart failure). Nevertheless, in practice, other ARBs may well also be used in this population because physicians frequently assume a class effect. A class effect implies that all drugs within a class have the same effects in a given population. The choice of one drug over another should ideally be supported by good clinical evidence, but there are few comparative studies among ARBs on which to base such a decision. Indeed, the logistics and cost of a comparative study of ARBs on cardiovascular outcomes are extremely daunting. Thus, assumptions of a class effect must necessarily also look to pharmacokinetic and pharmacodynamic parameters with potential clinical implications. If there are differences in structural features and pharmacological characteristics of drugs within the same class that can be shown to influence clinical properties then, in the absence of direct comparative clinical trial evidence, the assumption of a class effect may be inappropriate.
This review explores the physicochemical, pharmacological and pharmacokinetic attributes of telmisartan. It examines how these properties are likely to account for the physiological and clinical effects of telmisartan and how they may distinguish telmisartan from other members of the ARB class.
Molecular structure of telmisartan
Telmisartan has a novel bis-benzimidazole structure, 4 whereas candesartan, losartan, irbesartan and valsartan share a common tetrazolo-biphenyl structure 5 Differences between the molecular structures of ARBs are responsible for variations in lipid solubility, volume of distribution, bioavailability, biotransformation, plasma half-life, receptor affinity and residence time, and elimination. These different properties might drive the variations that are apparent in the physiological and pharmacodynamic effects of ARBs.
Angiotensin II type 1 receptor binding activity
Several distinct angiotensin II receptors exist which mediate the pathophysiological and physiological actions of the angiotensins. The angiotensin II type 1 (AT 1 ) receptor primarily found in blood vessels, the liver, kidneys, heart and brain, is considered to be responsible for the pathophysiological effects of angiotensin II (e.g. vasoconstriction, oxidative stress and inflammation). 6 Local activation of the renin-angiotensin system (RAS) can have deleterious effects on organ function and, therefore, inhibition of the AT 1 receptor may account for the beneficial effects of ARBs on renal and cardiovascular outcomes that extend beyond blood pressure. Angiotensin II type 2 (AT 2 ) receptors are located in many of the same organs as AT 1 receptors, but are generally thought to have physiologically opposing actions to AT 1 receptors. 6 Telmisartan is highly specific for the AT 1 receptor (K i = 3.7 ± 0.7 nM). 7 It has little or no affinity for the AT 2 receptor (K i > 10 000 nM) or for other neurohormonal receptor systems (i.e. acetylcholine, catecholamine, dopamine, histamine, serotonin or imipramine receptors). 8 Thus, telmisartan does not block the action of these other receptor systems that are involved in cardiovascular function.
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The biological consequences of the interaction of the AT 1 receptor with a drug are likely to be influenced by the kinetics of that interaction. Telmisartan is an insurmountable antagonist at the AT 1 receptor, i.e. the blockade is semi-irreversible, which is characterized by the slow release of the antagonist from its receptor. 8, 9 This antagonism reduces the maximal response to angiotensin II; when the receptor is preincubated with telmisartan, there is a nonparallel rightward shift of the angiotensin II dose-response curve. 8 The insurmountable antagonism is due to the slow dissociation of telmisartan from the AT 1 receptor. 8,10 Telmisartan binds to the AT 1 receptor with the strongest affinity of currently available ARBs. 10 When tested in an in vitro preparation of human AT 1 receptors, the dissociation half-life of telmisartan was 213 min, whereas those of the other ARBs ranged from 166 min with olmesartan to 67 min with losartan ( Fig. 1) . 10 Another in vitro study using a different methodology (human AT 1 receptors expressed in Chinese hamster ovary cells) found the dissociation half-life of telmisartan to be faster than that of olmesartan. 11 The AT 1 binding properties of telmisartan are likely to be important for its long-lasting antihypertensive effects.
Pharmacokinetics of telmisartan
Alongside interactions with the receptor, pharmacokinetic properties are important factors that influence the pharmacodynamics of a drug. Telmisartan is the most lipophilic of all ARBs, with a partition coefficient of log 3.2 (n-octanol/buffer at pH 7.4). 7 The high lipophilicity of telmisartan facilitates oral absorption and permits tissue and cell penetration. Moreover, this physicochemical property results in its high volume of distribution of approximately 500 l (7 l/kg). 12 In comparison, candesartan, valsartan, eprosartan and the active metabolite of losartan have smaller volumes of distribution (0.13 -0.24 l/kg) than telmisartan. A volume of distribution that is less than the volume of free water (0.6 l/kg) 
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indicates poor transfer to tissue. 12 The extensive tissue distribution of telmisartan is demonstrated by whole body autoradiography in rats in which telmisartan was detected in the liver, kidney, blood and lung. 12 The diverse pathophysiological effects that follow activation of the AT 1 receptor mean that the ability of telmisartan to block the receptor at systemic and local levels may help to reduce target organ damage.
Telmisartan is slowly eliminated after oral administration, with an elimination half-life of approximately 20 -30 h (Table 1) . 13, 14 Thus, the therapeutic effect of the drug is expected to be maintained throughout the 24-h dosing interval. The half-life of telmisartan is considerably longer than that of other ARBs (e.g. valsartan, approximately 9 h; candesartan, 3 -11 h; eprosartan, 5 -7 h; the active metabolite of eprosartan, 6 -9 h; and irbesartan, 11 -15 h) ( Fig. 2) . 15, 16 The contribution of the long half-life of telmisartan to its prolonged duration of action is demonstrated by its effects following an infusion of angiotensin II. At peak plasma concentrations (i.e. at 2 h), telmisartan 80 mg reduced the diastolic blood pressure response to exogenous angiotensin II in healthy volunteers by about 80%, and 40% inhibition was apparent after 24 h, with effects still observable 48 h after dosing. 17 Telmisartan does not significantly accumulate after oncedaily dosing.
Glucuronidation is the only metabolic pathway of telmisartan in humans. 18 Telmisartan does not induce or significantly inhibit cytochrome P450 and is not itself metabolized by phase I reactions. 18 There is, therefore, a low likelihood of clinically relevant interactions of telmisartan with drugs that are metabolized by cytochrome P450. In comparison, irbesartan is slightly 
metabolized (6% of the dose) by cytochrome P450 2C9 (CYP2C9) and losartan is metabolized by CYP2C9 and cytochrome P450 3A4 (CYP3A4). 19 Unlike some other ARBs, which are excreted to varying extents via the kidneys (10 -35% of the oral dose), 15, 16, 19 telmisartan is almost entirely eliminated in the faeces in animal models and in humans (> 98%) 20 ( Table 1) . 14 Thus, renal impairment is unlikely to affect the pharmacokinetics of telmisartan.
Telmisartan and inflammation
Cardiovascular disease is intimately linked with inflammation. 21 The role of inflammation in the pathogenesis and continuation of atherosclerosis is well recognized and there is a growing body of evidence suggesting that inflammation might contribute to the development of hypertension and its complications. 22 Studies with ARBs have demonstrated the importance of RAS blockade via the AT 1 receptor on outcomes of cardiovascular disease. 1 -3 All ARBs may, to some extent, share the anti-inflammatory effects that might be expected from inhibiting the effects of angiotensin II via AT 1 receptor blockade. How and which of these in vitro anti-inflammatory effects may account for differences in cardiovascular outcomes remains to be established. Angiotensin II induces inflammation through the upregulation of reactive oxygen species, adhesion molecules and inflammatory cytokines. 23 Nuclear factor (NF)-κB is a transcription factor that plays a pivotal role in the gene expression of these inflammation-related molecules and is upregulated following activation of the AT 1 receptor. 24 Telmisartan has been shown to down-regulate NF-κB and to inhibit its translocation through its action at the AT 1 receptor. 25 Telmisartan reduces oxidative stress in animal models. 26 -30 In addition, it increases endothelial nitric oxide synthase (eNOS) expression, which is likely to be important in the maintenance of endothelial function. 26, 31 Telmisartan also suppresses the leucocyte adhesion that precedes vascular complications through inhibitory effects on the expression of 
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inflammatory cytokines and adhesion molecules. 25, 30 In spontaneously hypertensive rats, telmisartan and losartan decreased expression of monocyte chemoattractant protein (MCP)-1, a pro-inflammatory cytokine that is involved in angiotensin IImediated atherosclerosis, and reduced monocyte/macrophage infiltration into the vascular wall. 32 This was associated with reductions in markers of remodelling of target organs such as blood vessels and heart. 32 Telmisartan demonstrates greater anti-inflammatory effects than other ARBs or ACE inhibitors in some studies. For example, in human umbilical vein endothelial cells, telmisartan, but not losartan or its active metabolite, reduced adhesion molecule gene expression and reduced oxidative damage. 33 Similarly, telmisartan reduced atherosclerotic lesion progression in mice and reduced the expression of inflammatory factors to a greater extent than ramipril, 34 whereas telmisartan and valsartan both inhibited diabetes-induced retinal expression of adhesion molecules and MCP-1 in vitro and in mouse retina to a similar extent. 25 In clinical studies, telmisartan has been shown to lower markers of inflammation in hypertensive patients. 35 In a small group of valsartan pre-treated patients, this reduction was found to be greater in hypertensive patients who were switched to telmisartan than in those who were maintained on valsartan. 36 In the latter group, there were no significant changes from baseline. 36 Similar results were found in a study among hypertensive patients who received telmisartan or valsartan after sirolimuseluting stent insertion. 37 Only telmisartan was associated with a significant decrease in late-lumen loss and inflammatory markers. 37 In general, it appears that RAS blockers reduce plasma (serum) levels of C-reactive protein (CRP), a marker of inflammation, although findings with candesartan and losartan have been inconsistent. 38 Telmisartan reduced CRP levels in patients with type 2 diabetes, albeit to a lesser extent than olmesartan. 39 Reductions in CRP levels were also observed in telmisartan-treated hypertensive patients with metabolic syndrome and the decrease was greater than in valsartan-treated patients. 36 A recent study in patients with metabolic syndrome after heart transplantation did not, however, find an effect of telmisartan on CRP. 40
PPARg agonist properties of telmisartan
Telmisartan is a partial agonist of peroxisome proliferator-activated receptor γ (PPARγ). 41 Its high lipophilicity allows it to penetrate into the nucleus where the PPARγ receptor is located. The ability of telmisartan to activate PPARγ appears to be separate from its AT 1 receptor blockade as it activates PPARγ in cells that do not possess the AT 1 receptor. 42 In an in vitro assay, only telmisartan caused strong (27-fold) PPARγ activation, although irbesartan and losartan showed slight activation (two-to three-fold; Fig.  3A ). 41 The activation with telmisartan is 25 -30% of the maximum level obtained with PPARγ agonists (Fig. 3B ). 41 At plasma concentrations that can be achieved with conventional oral dosing, only telmisartan activated this receptor. 41 In another study comparing ARBs in an in vitro system, only telmisartan resulted in significant PPARγ agonism. 43 Adiponectin production by adipocytes is a marker of PPARγ agonism in vivo 44, 45 and telmisartan increased adiponectin levels in many but not all clinical studies. 35, 46, 47 
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Differences in adiponectin levels illustrate intra-class differences in PPARγ agonism among ARBs. In comparative studies, telmisartan increased adiponectin levels to a greater extent than valsartan, 36,37 irbesartan 48 or candesartan. 46, 47 Although an increase in adiponectin level is considered to be a marker of PPARγ activation, it has been suggested that telmisartan stimulates adiponectin gene expression by a PPARγindependent mechanism. 49 The expression of genes involved in carbohydrate and lipid metabolism is also influenced by PPARγ. 50 The effects of telmisartan, particularly on glucose metabolism and insulin resistance, are typical of PPARγ agonists, although some studies have not demonstrated all the effects of PPARγ agonism. 40,51 -56 As a partial agonist of PPARγ, telmisartan does not, however, cause the adverse effects of fluid retention and weight gain that are associated with full PPARγ agonists (e.g. rosiglitazone). 41 Of note, telmisartan has been found to prevent the weight gain induced by glitazones, an effect that was found to be independent of its insulinsensitizing properties. 57 The metabolic effects of telmisartan are generally larger than those seen with other ARBs, although not all studies have shown differences in all parameters between telmisartan and comparator ARBs. For example, in studies in patients with metabolic syndrome, telmisartan lowered insulin resistance significantly more than losartan 58,59 or valsartan. 36, 60 In patients with diabetes, telmisartan and irbesartan produced similar reductions in blood pressure and reduced low-density lipoprotein cholesterol (LDL-C) and total cholesterol levels after 6 and 12 months. 61 Only the telmisartan group had significant improvements at 6 months in haemoglobin A E X P 3 1 7 4 V a l s a r t a n C a n d e s a r t a n O l m e s a r t a n I r b e s a r t a n T e l m i s a r t a n 
A1c, fasting plasma glucose, insulin resistance and adiponectin levels. 61 Although both drugs were associated with improvements in these parameters at 12 months, the improvements were significantly larger with telmisartan. 61 In another comparison of these two ARBs in hypertensive diabetic patients, telmisartan resulted in greater improvements in the metabolic profile (plasma glucose, cholesterol, triglycerides, free fatty acids, steady-state plasma insulin and plasma glucose) than irbesartan. 48 In patients with type 2 diabetes and mild hypertension, no changes in glucose metabolism were apparent on treatment with telmisartan 40 mg or eprosartan 600 mg, but telmisartan was more effective in improving dyslipidaemia (i.e. LDL-C, total cholesterol and triglycerides). 61 An additional property of PPARγ agonists is their ability to ameliorate inflammation, partly through inhibition of NF-κB and activator protein-1. 34, 62, 63 Advanced glycation end-products (AGE) contribute to endothelial cell damage by binding to the receptor for advanced glycation endproducts (RAGE). 64 This leads to activation of NF-κB and the development of inflammation. 64 Telmisartan has been shown to suppress the expression of RAGE at the mRNA and protein levels, an effect that was prevented by a PPARγ inhibitor, 65 and to decrease levels of soluble RAGE in patients. 66 Telmisartan and a PPARγ agonist, but not valsartan, inhibited NF-κB-dependent gene transcription in vascular smooth muscle cells. 67 Telmisartan dose-dependently reduced AGE-induced generation of reactive oxygen species and the subsequent production of CRP, while candesartan had no effect. 68 This action of telmisartan was blocked by a PPARγ antagonist. 68 Although telmisartan exhibited greater antiinflammatory and oxidative effects than losartan in human umbilical vein endothelial cells, PPARγ inhibitors did not, however, influence the effects of telmisartan. 33 Migration of T-cells into the vessel wall is an early event in atherosclerosis. 69 In common with thiazolidinediones, telmisartan inhibits lymphocyte migration whereas eprosartan does not, suggesting that the effect is due to PPARγ agonism and independent of AT 1 activation. 70 Thus, the extent to which PPARγ activation by telmisartan contributes to its anti-inflammatory effects at a vascular level remains to be confirmed.
Telmisartan and endothelial function
Angiotensin II induces endothelial dysfunction through inflammation and oxidative stress. 71 Endothelial dysfunction is an early event in vascular pathophysiology and involves processes that have been implicated in hypertension, atherosclerosis and renal disease. 72 ARBs and ACE inhibitors have beneficial effects on endothelial function that are not apparent for other classes of antihypertensives, 73, 74 and differences among ARBs are also apparent. 75 -77 At doses producing equivalent blood pressure-lowering effects, telmisartan 40 mg/day had more favourable effects on markers of endothelial function than valsartan 80 mg/day. 76 The Telmisartan versus Ramipril in renal ENdothelial DYsfunction in type 2 diabetes (TRENDY) trial was the first study to investigate RAS inhibition on endothelial function in the kidney and to compare two antihypertensive classes. 75 Telmisartan 40 -80 mg and ramipril 5 -10 mg were studied for 9 weeks in 96 hypertensive type 2 diabetic patients who had a glomerular filtration rate (GFR) > M Burnier Telmisartan in at-risk cardiovascular patients 80 ml/min and normo-or microalbuminuria. 75 Endothelial function was assessed in TRENDY by measuring the changes in renal plasma flow after administration of an inhibitor of nitric oxide (NO) formation (N G -monomethyl-L-arginine [L-NMMA]). 75 Telmisartan and ramipril improved endothelial function compared with baseline, although there was a numerically greater fall in renal plasma flow in response to L-NMMA with telmisartan (the magnitude of the decrease corresponding with the level of pre-existing NO activity). 75 Telmisartan also resulted in a significant change in resting renal plasma flow, whereas ramipril did not affect this parameter. 75 The improvement in basal NO activity during telmisartan treatment correlated with vasodilation in the renal vasculature, but was independent of systemic blood pressure. 75 Thus, telmisartan and ramipril have different effects on endothelial function in the kidney.
In keeping with its effects on endothelial dysfunction, telmisartan reduces arterial stiffness as indicated by reductions in pulse wave stiffness index in healthy volunteers 78 and in pulse wave velocity in patients with type 2 diabetes. 79 The mechanisms underlying this improvement in endothelial function with telmisartan are likely to be attributable to the effects of AT 1 receptor blockade and PPARγ agonism on NO production, oxidative stress and inflammation. The clinical consequences of the changes in endothelial function observed with telmisartan, however, remain to be clarified. Indeed, despite a significant difference with ramipril in the TRENDY study, results of the ONTARGET™ trial did not demonstrate any difference on morbidity and mortality between telmisartan and ramipril. 1 Thus, whether endothelial function is a valid surrogate marker of cardiovascular risk remains to be demonstrated.
Antihypertensive effect of telmisartan compared with other ARBs
Ambulatory blood pressure monitoring (ABPM) studies have shown that telmisartan provides more powerful blood pressure reductions than losartan and valsartan. 80 -84 In two studies of similar design reported by Lacourcière et al. 83 , telmisartan 80 mg achieved superior blood pressure control over valsartan 160 mg at the end of the treatment period. Seated systolic blood pressure (SBP) also differed between the two ARBs; it was significantly lower with telmisartan than with valsartan treatment (12.1 versus 8.2 mmHg, respectively; P = 0.0281), the reduction in diastolic blood pressure (DBP) was numerically greater with telmisartan. In an analysis of pooled data from the two studies published in the same report, 83 telmisartan decreased the last 6-h mean DBP to a greater extent than valsartan (7.6 versus 5.8 mmHg, respectively; P = 0.0044) and gave larger reductions in the last 6-h mean SBP (11.1 versus 9.1 mmHg, respectively; P = 0.0066). Another study found, however, that valsartan 160 mg provided larger 24-h mean reductions in SBP and DBP (18.6 and 12.1 mmHg) than telmisartan 80 mg (10.8 and 8.4 mmHg). 85 The benefit of the long duration of action of telmisartan is apparent after a missed dose. 83 After a deliberately missed dose in the two ABPM studies, the reduction in 24-h mean SBP was significantly greater with telmisartan than with valsartan (10.7 versus 8.7 mmHg, respectively; P = 0.0024) as was the reduction in 24-h mean DBP (7.2 versus 5.5 mmHg, respectively; P = 0.0004). 83 Thus, telmisartan provides more powerful blood M Burnier Telmisartan in at-risk cardiovascular patients pressure lowering and sustained efficacy than valsartan in poorly compliant patients in the event of a missed dose. 83 Telmisartan 40 or 80 mg provided more powerful reductions than losartan in both 24h mean SBP and DBP in three ABPM studies. The duration of blood pressure control was significantly longer with telmisartan than with losartan, as illustrated by greater reductions in blood pressure during the last 6 h of the dosing interval with telmisartan 40 mg than losartan 50 mg 80, 82, 84 and with telmisartan 80 mg versus losartan 100 mg. 82 In a study using cuff measurement of blood pressure, trough blood pressure levels were significantly lower with telmisartan (40 -80 mg) than with losartan (50 -100 mg). 86 In a home blood pressure measurement study among Japanese hypertensive patients, telmisartan reduced blood pressure more than other ARBs. 87 Telmisartan 10 -40 mg gave greater blood pressure reductions in the early morning period than valsartan 40 -80 mg, candesartan 2 -12 mg, or losartan 25 -100 mg. 87 In particular, the effect of losartan did not persist for 24 h when comparing the morning effect on blood pressure with the evening effect. 87 A 1-year comparative study in patients with mild hypertension and type 2 diabetes showed that telmisartan 40 mg produced a superior reduction in blood pressure compared with the short-acting ARB eprosartan 600 mg. 61
Telmisartan and renal function
Renal pathology may be affected by ACE inhibitors and ARBs by the lowering of glomerular pressure and by preventing angiotensin II-induced inflammation and oxidative stress. 75, 88, 89 Telmisartan has been shown to delay the onset and to retard the progression of diabetic nephropathy; 88,90 but the mechanism for this is not fully understood. Its PPARγ agonist property may play a role, as PPARγ receptor activation ameliorates glucose-induced inflammation and oxidative stress, and has antifibrotic effects by diminishing inflammatory cytokine production and fibronectin in renal cells. 91 ARBs with no or fewer PPARγ agonistic activities than telmisartan have also, however, been shown to retard the progression of diabetic nephropathy. 92, 93 Telmisartan reduces the transition to overt nephropathy 94 and is as effective as enalapril in slowing the decline in GFR among patients with type 2 diabetes and either micro-or macroalbuminuria. 88 The Diabetics Exposed to Telmisartan And enalaprIL (DETAIL) study demonstrated the long-term benefit of telmisartan on GFR. 88 A decline in GFR over the first year of DETAIL was apparent with telmisartan and enalapril, 88 but probably reflected a haemodynamic effect as a similar phenomenon has occurred with other ARBs and ACE inhibitors. 95 Thereafter, the annual decline in GFR was much lower, stabilizing at approximately 2 ml/min per 1.73 m 2 after 3 years. 88 This is much lower than the typical 10 -12 ml/min per 1.73 m 2 decline that occurs in untreated diabetics with macroalbuminuria but was comparable with enalapril and telmisartan, demonstrating the importance of controlling blood pressure and inhibiting the RAS for renal protection. 88 The effect of telmisartan on macroalbuminuria was evaluated in A trial to compare telMisartan 40 mg titrated to 80 mg versus losArtan 50 mg titrated to 100 mg in hypertensive type 2 DiabEtic patients with Overt nephropathy (AMADEO), 96 and in the inVestigate the efficacy of mIcardis versus VALsartan in hypertensive type 2 DIabetic patients with overt nephropathy (VIVALDI) study. 90
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In AMADEO, patients were treated with telmisartan 80 mg/day or losartan 100 mg/day. 96 If blood pressure was not controlled, other antihypertensive therapies could be added; there was no significant difference in adjunctive therapies between the treatment arms in the study. 96 A 52-week randomized period was followed by a 2month drug-free follow-up period in 346 patients. 96 Telmisartan reduced the primary endpoint of urinary protein:creatinine ratio significantly more than losartan after 52 weeks (29% versus 20% from baseline, respectively; P = 0.03), despite similar blood pressure control; although better control of night-time blood pressure with telmisartan cannot be excluded. 96 Over the 2-month follow up, a continued antiproteinuric effect of telmisartan was apparent. 96 The difference in urinary protein:creatinine ratio in AMADEO could suggest that there are intra-class differences in the renal effects of ARBs. 96 The AMADEO authors suggested that PPARγ agonism by telmisartan could have contributed to the antiproteinuric effect, as may the higher affinity for the AT 1 receptor, although it is not known if these attributes translate into a better antiproteinuric effect. 96 Blood pressure effects were largely discounted by the authors, who noted that there were no data to support the concept that the small blood pressure differences in the study translate into an effect on proteinuria. 96 Yet, a difference in night-time blood pressure due to the longer duration of action of telmisartan cannot be ruled out and may have contributed to the greater effect of telmisartan on 24-h urinary albumin excretion. Additionally, the different types of adjunctive antihypertensive agents were used to the same extent in the two treatment arms, which suggests that proteinuria was not influenced by adjunctive therapy. 96 There were also no differences in factors known to affect proteinuria (e.g. estimated GFR and serum aldosterone). 96 In VIVALDI, telmisartan 80 mg and valsartan 160 mg gave similar reductions in urinary protein excretion from baseline (33%), and there were no significant differences in secondary endpoints (serum creatinine, creatinine clearance or estimated GFR changes) between the ARBs. 90 In contrast, another study found that telmisartan significantly reduced microalbuminuria in hypertensive patients with metabolic syndrome, whereas valsartan had no effect. 36 The discordant findings between the AMADEO and VIVALDI studies may reflect methodological differences; the primary endpoint in AMADEO was the urinary protein:creatinine ratio, but it was 24-h urinary protein in VIVALDI. 90, 96 In addition, patients in the valsartan arm required adjunctive antihypertensive therapy more often than subjects in the telmisartan group in VIVALDI, 90 whereas there was no difference among treatment arms in AMADEO. 96 Furthermore, 80% of subjects in the VIVALDI trial were Caucasian compared with 45% in AMADEO, 90, 96 although the implications of this difference in ethnic distribution between studies is unclear.
Telmisartan in LVH and atrial fibrillation
Left ventricular hypertrophy (LVH) in hypertensive patients significantly increases the risks of coronary heart disease, stroke and heart failure. 97 Hypertension is a risk factor for LVH, but angiotensin II also has a direct proliferative effect that is likely to play a part in cardiac remodelling. 98 Telmisartan reduces left ventricular mass and left atrial size, 99 -101 and the regression of left ventricular mass is greater than that with M Burnier Telmisartan in at-risk cardiovascular patients carvedilol or hydrochlorothiazide. 100, 102 Angiotensin II plays a pivotal role in the pathophysiology of atrial fibrillation, 103 -105 which increases the long-term risk of allcause mortality, stroke and heart failure. 106 Experimental evidence suggests that ARBs can influence atrial re-modelling and some clinical studies suggest that they may prevent the recurrence of atrial fibrillation. 107 -111 In hypertensive patients who did not require anti-arrhythmic therapy, telmisartan was significantly more efficacious than carvedilol in preventing or delaying the recurrence of atrial fibrillation. 107 The differences between these agents were not related to changes in blood pressure or left atrial size, but may be due to the effects of telmisartan on electrical remodelling. 112
Telmisartan and cardiovascular protection
The ONTARGET™ study compared telmisartan with the gold standard, ramipril, in at-risk ACE inhibitor-tolerant patients who did not have heart failure. 1 Telmisartan was non-inferior to ramipril; the primary composite outcome of cardiovascular death, MI, stroke or hospitalization for congestive heart failure occurred in 1423 patients (16.7%) in the telmisartan group compared with 1412 patients (16.5%) in the ramipril group. 1 The results for the secondary outcomes of death from cardiovascular causes, MI or stroke (i.e. the endpoint used in the Heart Outcomes Prevention Evaluation [HOPE] study 113 ) were consistent with those of the primary outcome. 1 Even though individuals who were intolerant to ACE inhibitors had been excluded from the trial, telmisartan was better tolerated than ramipril, e.g. lower rates of cough (1.1% versus 4.2%, respectively; P < 0.001) and angiooedema (0.1% versus 0.3%, respectively; P = 0.01), and was associated with better treatment adherence, 1 findings that are likely to have clinical importance as patients require lifelong therapy to reduce cardiovascular risk.
The cardiovascular protective effects of telmisartan were compared with the best standard of care among patients unable to tolerate ACE inhibitors in the Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) study. 114 The study did not meet its primary endpoint, which was the same as that in the ONTARGET™ study (hazard ratio 0.92; 95% confidence interval [CI] 0.81 -1.05; P = 0.216). 1, 114 The secondary outcome of cardiovascular death, MI or stroke (i.e. the endpoint used in the HOPE study) was, however, significantly reduced by telmisartan compared with the best standard of care (hazard ratio 0.87; 95% CI 0.76 -1.00; P = 0.048). 104 The TRANSCEND study was probably underpowered as the patients in the trial were inherently better protected than those in the HOPE study, the trial on which the sample size calculations for the TRANSCEND study were based. 114 For example, statin use was 93% higher in TRANSCEND (i.e. 29% of patients in HOPE versus 55% of patients in TRANSCEND). 114 A further confounding factor was that there were higher rates of concomitant therapy use, particularly diuretics and β-blockers, in the best standard of care arm. 114 The trend of cardiovascular protection in TRANSCEND is supported by similar trends in the Prevention Regimen for Effectively avoiding Second Strokes (PRoFESS) study. 115 In a preplanned analysis of the two trials, telmisartan significantly reduced the odds of cardiovascular death, MI, stroke or hospitalization for heart failure by 7% and of the HOPE study endpoint by 9%. 115 Other ARBs have been shown to be effective in improving outcomes in patients with essential hypertension and left M Burnier Telmisartan in at-risk cardiovascular patients ventricular hypertrophy, increasing survival rates after MI and lowering mortality in patients with heart failure. It is likely that the pathogenic mechanisms in these populations and their co-morbidities, particularly in heart failure, are different to those in the subjects that comprised the ONTARGET™ population. The particular properties of telmisartan may well have contributed to the cardiovascular protection in ONTARGET™. 1 At a more fundamental level, ARBs show dose dependency for many of their effects, some of which may affect cardiovascular risk factors. 116 The telmisartan 80 mg dose was studied in ONTARGET™; 1 in this era of evidence-based medicine, it would be important to establish the actual dose of any other ARB that would be as efficacious as telmisartan 80 mg in providing protection in at-risk patients.
Conclusions
Telmisartan is a highly selective ARB with a novel bis-benzimidazole structure. Differences between the molecular structures of ARBs are responsible for variations in lipid solubility, distribution, bioavailability, biotransformation, plasma half-life and elimination. All of these factors contribute to differences in their duration of action and, therefore, affect their physiological effects. Telmisartan has a long half-life, high lipophilicity and large volume of distribution. This facilitates RAS inhibition at systemic and local levels. When binding to the AT 1 receptor, telmisartan has one of the highest affinities and longest durations of blockade among the ARBs. Together, these properties may explain the powerful and long-lasting reductions in blood pressure achieved with telmisartan, that are greater than those of valsartan and losartan. They may also contribute to the anti-inflammatory effects of telmisartan. A further distinguishing feature is that telmisartan is a partial PPARγ agonist at therapeutic doses. PPARγ agonism is likely to contribute to the improvements in glucose metabolism, lipid metabolism and inflammation seen with telmisartan, which are generally greater than those of comparator ARBs.
The profile of telmisartan is likely to have played a key part in determining the extent of its cardiovascular protective effects in the ONTARGET™ study. 1 Telmisartan was as effective as the gold standard, ramipril, in reducing cardiovascular risk in a broad cross-section of at-risk cardiovascular ACE inhibitor-tolerant patients, while being better tolerated and being associated with greater treatment persistence. Although the placebo-like tolerability is common to ARBs, it cannot be assumed that the degree of protection provided by telmisartan will be the same across the class as there are differences between it and other members of the class in attributes that influence efficacy.
In summary, a class effect for ARBs cannot be assumed. The ARBs that have been shown to be effective in improving outcomes in specific patient populations should be used in those patients. Telmisartan is the only ARB that has been proven to provide protection in patients with complicated diabetes or evidence for coronary artery disease without heart failure. In the VALUE trial in patients with hypertension and increased risk of cardiac events, valsartan did not reduce cardiovascular morbidity and mortality better than amlodipine. 2 Telmisartan should, therefore, be used to reduce cardiovascular risk in at-risk cardiovascular patients.
